Teva (TEVA) furnishes 8-K with 2025 full-year and Q4 results press release

Rhea-AI Filing Summary

Teva Pharmaceutical Industries Limited furnished an update on its business performance by submitting an 8-K tied to its latest earnings release. On January 28, 2026, the company issued a press release detailing financial results for the period ended December 31, 2025, covering both full-year 2025 and fourth quarter performance. This press release is provided as Exhibit 99.1 and is incorporated by reference into the report, but the underlying financial figures and metrics appear only in the exhibit itself. The 8-K specifies that this earnings information is being furnished rather than filed, which affects how it is treated under U.S. securities laws.

False000081868600008186862026-01-282026-01-28iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  January 28, 2026

_______________________________

TEVA PHARMACEUTICAL INDUSTRIES LIMITED

(Exact name of registrant as specified in its charter)

_______________________________

Israel	001-16174	Not Applicable
(State or other jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification Number)

124 Dvora Hanevi’a Street

Tel Aviv 6944020, Israel

(Address of Principal Executive Offices, including Zip Code)

+972-3-914-8213

(Registrant's Telephone Number, including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
American Depositary Shares, each representing one Ordinary Share	TEVA	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On January 28, 2026, Teva Pharmaceutical Industries Ltd. issued a press release announcing its financial results for the period ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and the information contained therein is incorporated herein by reference.

The information included in this Item 2.02 is being furnished to the Securities and Exchange Commission and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description of Document
99.1		Teva Reports 2025 Full Year and Fourth Quarter Financial Results
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Date: January 28, 2026	By:	/s/ Eli Kalif
		Eli Kalif
		Executive Vice President, Chief Financial Officer

FAQ

What did Teva (TEVA) disclose in this 8-K filing?

Teva furnished an 8-K to provide investors with a press release containing its financial results for the period ended December 31, 2025. The filing centers on full-year 2025 and fourth quarter results, which are detailed in Exhibit 99.1 attached to the report.

Which period do Teva’s newly reported financial results cover?

Teva’s reported financial results cover the period ended December 31, 2025, including both full-year 2025 and fourth quarter performance. The specifics of revenue, profit, and other metrics are contained in the press release furnished as Exhibit 99.1 to the 8-K.

How did Teva (TEVA) provide its 2025 full-year and Q4 results?

Teva provided its 2025 full-year and fourth quarter results through a press release issued on January 28, 2026. That press release, titled "Teva Reports 2025 Full Year and Fourth Quarter Financial Results," is furnished as Exhibit 99.1 within the 8-K filing.

Is Teva’s earnings information in this 8-K considered filed or furnished?

Teva’s earnings information in this 8-K is expressly described as furnished, not filed, under the Securities Exchange Act of 1934. This distinction limits how the information is treated for liability and incorporation by reference into other securities law filings.

Where can investors find the detailed numbers for Teva’s 2025 results?

Investors can find detailed numbers for Teva’s 2025 full-year and fourth quarter results in Exhibit 99.1 to the 8-K. That exhibit contains the complete earnings press release, which includes the underlying financial metrics and commentary referenced in the current report.